ES3009437T3 - Use of pridopidine for treating dystonias - Google Patents
Use of pridopidine for treating dystonias Download PDFInfo
- Publication number
- ES3009437T3 ES3009437T3 ES17844432T ES17844432T ES3009437T3 ES 3009437 T3 ES3009437 T3 ES 3009437T3 ES 17844432 T ES17844432 T ES 17844432T ES 17844432 T ES17844432 T ES 17844432T ES 3009437 T3 ES3009437 T3 ES 3009437T3
- Authority
- ES
- Spain
- Prior art keywords
- dystonia
- pridopidine
- uhdrs
- pharmaceutical composition
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010118 dystonia Diseases 0.000 title claims abstract description 254
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title claims abstract description 190
- 229950003764 pridopidine Drugs 0.000 title claims abstract description 183
- 208000014094 Dystonic disease Diseases 0.000 claims abstract description 273
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 230000008859 change Effects 0.000 claims description 105
- 208000023105 Huntington disease Diseases 0.000 claims description 70
- 230000006872 improvement Effects 0.000 claims description 70
- 238000011282 treatment Methods 0.000 claims description 57
- 238000012360 testing method Methods 0.000 claims description 44
- 208000024891 symptom Diseases 0.000 claims description 22
- 230000002068 genetic effect Effects 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 230000033001 locomotion Effects 0.000 claims description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 9
- 230000000926 neurological effect Effects 0.000 claims description 9
- 230000000737 periodic effect Effects 0.000 claims description 9
- 208000022124 combined dystonia Diseases 0.000 claims description 8
- 208000013454 early-onset generalized dystonia Diseases 0.000 claims description 8
- 201000002886 generalized dystonia Diseases 0.000 claims description 8
- 101000662686 Homo sapiens Torsin-1A Proteins 0.000 claims description 7
- 102100037454 Torsin-1A Human genes 0.000 claims description 7
- 230000002159 abnormal effect Effects 0.000 claims description 7
- -1 aconate Chemical compound 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 208000015543 Isolated dystonia Diseases 0.000 claims description 6
- 229960003638 dopamine Drugs 0.000 claims description 6
- 230000004118 muscle contraction Effects 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 208000011093 Myoclonus-dystonia syndrome Diseases 0.000 claims description 5
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims description 5
- 208000018688 Rapid-onset dystonia-parkinsonism Diseases 0.000 claims description 5
- 206010044565 Tremor Diseases 0.000 claims description 5
- 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 claims description 5
- 201000003346 myoclonic dystonia Diseases 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 201000002899 segmental dystonia Diseases 0.000 claims description 5
- 241000567030 Ampulloclitocybe clavipes Species 0.000 claims description 4
- 206010043101 Talipes Diseases 0.000 claims description 4
- 208000013142 Writer cramp Diseases 0.000 claims description 4
- 201000011228 clubfoot Diseases 0.000 claims description 4
- 201000002904 focal dystonia Diseases 0.000 claims description 4
- 201000002865 focal hand dystonia Diseases 0.000 claims description 4
- 201000002842 hemidystonia Diseases 0.000 claims description 4
- 201000002901 multifocal dystonia Diseases 0.000 claims description 4
- 230000001144 postural effect Effects 0.000 claims description 4
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 206010044074 Torticollis Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- 229940050390 benzoate Drugs 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 3
- 229940114081 cinnamate Drugs 0.000 claims description 3
- 229940001468 citrate Drugs 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 229950005627 embonate Drugs 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims description 3
- 208000018197 inherited torticollis Diseases 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 3
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
- 229960001860 salicylate Drugs 0.000 claims description 3
- 229940075554 sorbate Drugs 0.000 claims description 3
- 229940114926 stearate Drugs 0.000 claims description 3
- 229940086735 succinate Drugs 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 201000001340 torsion dystonia 1 Diseases 0.000 claims description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 101150002038 TOR1A gene Proteins 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 14
- 238000010079 rubber tapping Methods 0.000 description 58
- 239000000902 placebo Substances 0.000 description 51
- 229940068196 placebo Drugs 0.000 description 51
- 210000003811 finger Anatomy 0.000 description 34
- 230000000694 effects Effects 0.000 description 25
- 206010008748 Chorea Diseases 0.000 description 22
- 230000005021 gait Effects 0.000 description 22
- 208000012601 choreatic disease Diseases 0.000 description 20
- 230000000875 corresponding effect Effects 0.000 description 20
- 238000002565 electrocardiography Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 15
- 210000003414 extremity Anatomy 0.000 description 14
- 208000012661 Dyskinesia Diseases 0.000 description 13
- 208000015592 Involuntary movements Diseases 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 13
- 230000009850 completed effect Effects 0.000 description 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 11
- 229910052805 deuterium Inorganic materials 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 230000036544 posture Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000001149 cognitive effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000007476 Maximum Likelihood Methods 0.000 description 6
- 208000016285 Movement disease Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000000632 dystonic effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 101150109352 acr-16 gene Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 4
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 4
- 101150043003 Htt gene Proteins 0.000 description 4
- 241001625930 Luria Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 101100202644 Parasynechococcus marenigrum (strain WH8102) bsmB gene Proteins 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 230000036314 physical performance Effects 0.000 description 4
- 230000001020 rhythmical effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 230000002747 voluntary effect Effects 0.000 description 4
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 244000208734 Pisonia aculeata Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000002636 symptomatic treatment Methods 0.000 description 3
- 210000003813 thumb Anatomy 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 102000021527 ATP binding proteins Human genes 0.000 description 2
- 108091011108 ATP binding proteins Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010067671 Disease complication Diseases 0.000 description 2
- 101710107143 Dopamine receptor 1 Proteins 0.000 description 2
- 206010013887 Dysarthria Diseases 0.000 description 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 241000935974 Paralichthys dentatus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008909 emotion recognition Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000012002 interactive response technology Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000004731 long QT syndrome Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- MKIBUMXSJANYQB-HNNXBMFYSA-N (2s)-2-(3-methylsulfonylphenyl)-1-propylpiperidine Chemical compound CCCN1CCCC[C@H]1C1=CC=CC(S(C)(=O)=O)=C1 MKIBUMXSJANYQB-HNNXBMFYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- MGDKBCNOUDORNI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].[K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O MGDKBCNOUDORNI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241001112258 Moca Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010073211 Postural tremor Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 208000014370 Psychogenic movement disease Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 102000014327 Torsin-1A Human genes 0.000 description 1
- 108050003322 Torsin-1A Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 230000003493 anti-dystonic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002598 diffusion tensor imaging Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 101150113725 hd gene Proteins 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000011487 inherited dystonia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 108010000849 leukocyte esterase Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- SEMYAGXUFFHEEB-UHFFFAOYSA-M magnesium;potassium;chloride Chemical compound [Mg+2].[Cl-].[K+] SEMYAGXUFFHEEB-UHFFFAOYSA-M 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012034 trail making test Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US201662395319P | 2016-09-15 | 2016-09-15 | |
| PCT/US2017/048458 WO2018039475A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating dystonias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3009437T3 true ES3009437T3 (en) | 2025-03-26 |
Family
ID=61246309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17844432T Active ES3009437T3 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating dystonias |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11826361B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3503890B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7278210B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110012661A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017315781B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019003731A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3035099C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3503890T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3009437T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019002190A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3503890T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018039475A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| UA122999C2 (uk) | 2013-06-21 | 2021-02-03 | Прайлінія Н'Юротерапьютікс Лтд. | Застосування придопідину для лікування хвороби гантінгтона |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| EP3503890B1 (en) | 2016-08-24 | 2024-12-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating dystonias |
| MX390627B (es) | 2016-08-24 | 2025-03-21 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
| BR112021015346A2 (pt) | 2019-02-04 | 2021-10-05 | Prilenia Neurotherapeutics Ltd. | Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo |
| JP7603713B2 (ja) * | 2020-05-04 | 2024-12-20 | プリレニア ニューロセラピューティクス リミテッド | 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療 |
| KR20250121149A (ko) * | 2022-12-27 | 2025-08-11 | 프리레니아 뉴로테라퓨틱스 엘티디. | 소아 헌팅턴병 치료를 위한 프리도피딘 |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
| WO2025188979A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| BRPI0511907A8 (pt) * | 2004-06-08 | 2018-05-02 | A Carlsson Res Ab | novos derivados de fenilpiperidinas/piperazinas dissubstituídos como moduladores da neurotransmissão de dopamina |
| SE0401465D0 (sv) * | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| WO2008127188A1 (en) | 2007-04-12 | 2008-10-23 | Allbay Ab | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| US8562488B2 (en) * | 2009-10-05 | 2013-10-22 | The Cleveland Clinic Foundation | Systems and methods for improving motor function with assisted exercise |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| EP2753603B1 (en) | 2011-09-07 | 2017-06-21 | Teva Pharmaceuticals International GmbH | Polymorphic form of pridopidine hydrochloride |
| WO2013086425A1 (en) | 2011-12-08 | 2013-06-13 | IVAX International GmbH | The hydrobromide salt of pridopidine |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| US20140037850A1 (en) * | 2012-08-06 | 2014-02-06 | General Electric Company | Corrosion and wear resistant organic coatings |
| UA122999C2 (uk) * | 2013-06-21 | 2021-02-03 | Прайлінія Н'Юротерапьютікс Лтд. | Застосування придопідину для лікування хвороби гантінгтона |
| JP6949487B2 (ja) | 2014-01-22 | 2021-10-13 | プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ | プリドピジンの調節放出製剤 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| MX390627B (es) | 2016-08-24 | 2025-03-21 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
| EP3503890B1 (en) | 2016-08-24 | 2024-12-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating dystonias |
| US20200375966A1 (en) | 2016-09-15 | 2020-12-03 | Prilenia Therapeutics Development Ltd | Use of pridopidine for the treatment of anxiety and depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| CN109982686A (zh) | 2016-09-16 | 2019-07-05 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗rett综合征的用途 |
| HUE068300T2 (hu) | 2017-01-20 | 2024-12-28 | Prilenia Neurotherapeutics Ltd | Pridopidin törékeny X szindróma kezelésében történõ alkalmazásra |
| ES2938546T3 (es) | 2017-08-14 | 2023-04-12 | Prilenia Neurotherapeutics Ltd | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina |
| CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
-
2017
- 2017-08-24 EP EP17844432.9A patent/EP3503890B1/en active Active
- 2017-08-24 PL PL17844432.9T patent/PL3503890T3/pl unknown
- 2017-08-24 CA CA3035099A patent/CA3035099C/en active Active
- 2017-08-24 BR BR112019003731A patent/BR112019003731A2/pt not_active IP Right Cessation
- 2017-08-24 WO PCT/US2017/048458 patent/WO2018039475A1/en not_active Ceased
- 2017-08-24 DK DK17844432.9T patent/DK3503890T3/da active
- 2017-08-24 MX MX2019002190A patent/MX2019002190A/es unknown
- 2017-08-24 AU AU2017315781A patent/AU2017315781B2/en active Active
- 2017-08-24 CN CN201780066796.2A patent/CN110012661A/zh active Pending
- 2017-08-24 JP JP2019531546A patent/JP7278210B2/ja active Active
- 2017-08-24 ES ES17844432T patent/ES3009437T3/es active Active
-
2019
- 2019-02-24 US US16/283,784 patent/US11826361B2/en active Active
-
2021
- 2021-05-06 JP JP2021078788A patent/JP7278327B2/ja active Active
-
2023
- 2023-10-19 US US18/489,846 patent/US20240075021A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11826361B2 (en) | 2023-11-28 |
| CA3035099C (en) | 2023-01-17 |
| EP3503890A1 (en) | 2019-07-03 |
| AU2017315781A1 (en) | 2019-04-11 |
| CA3035099A1 (en) | 2018-03-01 |
| US20240075021A1 (en) | 2024-03-07 |
| MX2019002190A (es) | 2019-09-11 |
| BR112019003731A2 (pt) | 2019-07-16 |
| WO2018039475A8 (en) | 2018-10-04 |
| JP7278210B2 (ja) | 2023-05-19 |
| DK3503890T3 (da) | 2025-01-27 |
| EP3503890B1 (en) | 2024-12-18 |
| JP2021119189A (ja) | 2021-08-12 |
| PL3503890T3 (pl) | 2025-03-24 |
| US20190192496A1 (en) | 2019-06-27 |
| EP3503890A4 (en) | 2020-05-06 |
| JP2019524897A (ja) | 2019-09-05 |
| WO2018039475A1 (en) | 2018-03-01 |
| AU2017315781B2 (en) | 2021-01-28 |
| CN110012661A (zh) | 2019-07-12 |
| JP7278327B2 (ja) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3009437T3 (en) | Use of pridopidine for treating dystonias | |
| ES3025836T3 (en) | Use of pridopidine for treating functional decline | |
| ES2879631T3 (es) | Pridopidina para el tratamiento de la enfermedad de Huntington | |
| US12390456B2 (en) | Pridopidine for treating Huntington's disease | |
| CA3083341C (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| US20230181548A1 (en) | Use of pridopidine for treating functional decline | |
| US20230355595A1 (en) | Use of pridopidine for treating functional decline | |
| US20250319076A1 (en) | Use of pridopidine and analogs for treating symptoms of huntington disease | |
| US20230330073A1 (en) | Use of pridopidine for treating functional decline | |
| US20250082619A1 (en) | Use of pridopidine for treating functional decline | |
| HK40115915A (en) | Use of pridopidine for treating functional decline | |
| EA041256B1 (ru) | Применение придопидина для лечения ухудшения функциональной способности | |
| HK40009736A (en) | Use of pridopidine for treating functional decline | |
| HK40009736B (en) | Use of pridopidine for treating functional decline | |
| Solntseva et al. | P. 4.021 Acetylcholinesterase inhibitor, donepezil, is a potent antagonist of potassium channels of neuronal membrane | |
| NZ751156B2 (en) | Use of pridopidine for treating functional decline |